Characterization of CMV-specific T cell responses in immunocompromised hosts

免疫受损宿主中 CMV 特异性 T 细胞反应的表征

基本信息

  • 批准号:
    10700143
  • 负责人:
  • 金额:
    $ 24.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-07 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

The most common infectious complication following organ transplantation is cytomegalovirus (CMV), resulting in increased allograft rejection and mortality. Current virology research suggests that the presence of antigen- specific “polyfunctional” T cells is essential for viral control; when encountering target, these rare cells are capable of producing multiple inflammatory cytokines (e.g., IFNg, TNFa, IL-2) and effecting rapid cytolysis, while those cells expressing only one (i.e., monofunctional) or no cytokines have been associated with progressively less protection. Unfortunately, assays for quantification of polyfunctional T cells remains arduous and lack inter-facility reproducibility; additionally, the mechanisms driving the generation and maintenance of such cells remains unknown. My preliminary data in kidney transplant recipients reveals that those lacking polyfunctional CMV responses are at increased risk of CMV reactivation. Importantly, I have also found that T cell exhaustion is not primarily responsible for discrepancies in CMV-associated functionality observed between patients with and without CMV reactivation, thereby suggesting alternative mechanisms. Therefore, based on preliminary data, the central hypothesis tested is that STAT5- and myc-dependent molecular reprogramming is necessary for the generation and maintenance of CMV-specific polyfunctional T cells, and that expansion of cells with an IL-7-based protocol recapitulates this reprogramming and will produce functional, long-lived cell-based therapies in the event of CMV reactivation. The proposed research will: (1) determine if a transcriptional profile may be used not only to quantify polyfunctional T cells but also identify SOT recipients at risk for CMV reactivation; (2) determine the critical role of STAT5 and myc activation and alterative metabolic pathways expression on the function of CMV-specific polyfunctional T cells; and (3) optimize cytokine-based protocols for the ex-vivo expansion of CMV-specific T cells by characterization of functional, proliferative, and metabolic parameters. My primary career goal is to obtain a tenure-track position and establish an independent research laboratory at a major biomedical institution. My long-term career goal is to establish a career as an independently-funded physician-scientist, with a particular focus in transplant immunology and associated changes in T cells metabolism. To achieve these goals, I will develop my intellectual base, strengthen my leadership skills, and enhance the necessary technical skills through the duration of the proposed study. Valuable training is readily available in the labs of Drs. Murdoch, Chao, and Piantadosi. Furthermore, to promote and bolster my progress during the award period, I have organized a scientific advisory committee of well-established scientists and clinicians with expertise in all areas of the application. Collectively, the proposed research will enhance our understanding of the specific molecular mechanisms regulating the generation and maintenance of polyfunctional T cells in transplant recipients, and may result in better treatment options for transplant recipients with CMV reactivation.
器官移植后最常见的感染并发症是巨细胞病毒(CMV),导致 增加了同种异体移植排斥反应和死亡率。目前的病毒学研究表明,抗原的存在- 特殊的“多功能”T细胞对于病毒控制是必不可少的;当遇到目标时,这些稀有细胞是 能够产生多种炎性细胞因子(例如,IFNG、TNFa、IL-2)并实现快速的细胞溶解, 而那些只表达一种(即,单功能)或不表达细胞因子的细胞与 保护力度越来越小。不幸的是,对多功能T细胞进行量化的分析仍然很困难 并且缺乏设施间的重复性;此外,驱动产生和维护 这样的细胞仍然未知。我在肾移植受者中的初步数据显示,那些缺乏 多功能巨细胞病毒应答增加了巨细胞病毒重新激活的风险。重要的是,我还发现T 细胞耗尽不是观察到的CMV相关功能差异的主要原因 在有和没有CMV重新激活的患者之间,从而提出了替代机制。因此, 根据初步数据,检验的中心假设是STAT5和myc依赖的分子 重新编程对于CMV特异性多功能T细胞的产生和维持是必要的,并且 使用基于IL-7协议的细胞扩展概括了这种重新编程,并将产生 在巨细胞病毒重新激活的情况下,基于细胞的功能性、长寿疗法。拟议的研究将:(1) 确定转录图谱是否不仅可以用来量化多功能T细胞,还可以用来识别 面临CMV重新激活风险的SO受体;(2)确定STAT5和myc激活的关键作用和 改变代谢途径对CMV特异性多功能T细胞功能的影响 优化基于细胞因子的CMV特异性T细胞体外扩增方案 功能、增殖和代谢参数。我的主要职业目标是获得终身教职的职位 并在一家大型生物医学机构建立独立的研究实验室。我的长期职业目标是 建立一个独立资助的内科科学家的职业生涯,特别是移植方面的重点 免疫学和T细胞代谢的相关变化。为了实现这些目标,我将发展我的 知识基础,加强我的领导能力,并通过 拟议研究的持续时间。有价值的培训在默多克博士、赵小兰博士和 皮安塔多西。此外,为了促进和支持我在获奖期间的进步,我组织了一个 由在各个领域都有专长的知名科学家和临床医生组成的科学咨询委员会 申请。总的来说,拟议的研究将增强我们对特定分子的理解 调节移植受者多功能T细胞的产生和维持的机制,以及 对于CMV重新激活的移植受者,可能会有更好的治疗选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zachary Ryan Healy其他文献

Zachary Ryan Healy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zachary Ryan Healy', 18)}}的其他基金

Characterization of CMV-specific T cell responses in immunocompromised hosts
免疫受损宿主中 CMV 特异性 T 细胞反应的表征
  • 批准号:
    10662620
  • 财政年份:
    2022
  • 资助金额:
    $ 24.59万
  • 项目类别:
Characterization of CMV-specific T cell responses in immunocompromised hosts
免疫受损宿主中 CMV 特异性 T 细胞反应的表征
  • 批准号:
    9976049
  • 财政年份:
    2020
  • 资助金额:
    $ 24.59万
  • 项目类别:
Characterization of CMV-specific T cell responses in immunocompromised hosts
免疫受损宿主中 CMV 特异性 T 细胞反应的表征
  • 批准号:
    10204982
  • 财政年份:
    2020
  • 资助金额:
    $ 24.59万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 24.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了